Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.42 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.42 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.42 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | DAO | P14920 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1006834 | 0.89 | ALOX15 (0.48) | ALOX15NFKB1BLMSMN1; SMN2GRIN2D | |
| SCHEMBL13804459 | 0.86 | GRIN2D (0.40) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL1160043 | 0.78 | KDM4E (0.48) | ALOX15SMN1; SMN2ALDH1A1HSD17B10KDM4E | |
| SCHEMBL10263146 | 0.77 | HRH4 (0.64) | — | |
| SCHEMBL18250045 | 0.75 | KDM4E (0.51) | ALOX15SMN1; SMN2ALDH1A1HSD17B10KDM4E | |
| SCHEMBL1004852 | 0.75 | ALDH1A1 (0.59) | ALOX15NFKB1BLMSMN1; SMN2GRIN2D | |
| SCHEMBL10264129 | 0.73 | ALDH1A1 (0.49) | ALOX15NFKB1BLMSMN1; SMN2GRIN2D | |
| SCHEMBL1423043 | 0.71 | ALDH1A1 (0.65) | ALOX15NFKB1BLMSMN1; SMN2GRIN2D | |
| SCHEMBL1005097 | 0.70 | CYP1A2 (0.49) | KDM4ELMNAKMT2AMAPK1TSHR | |
| SCHEMBL8168410 | 0.69 | ALDH1A1 (0.62) | ALOX15NFKB1BLMSMN1; SMN2GRIN2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630533-B2 | Heterocyclic compounds useful as KCNT1 inhibitors | ACTIO BIOSCIENCES, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20250313548-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS KCNT1 INHIBITORS | ACTIO BIOSCIENCES, INC. | 2025-10-09 | — | — | US | disclosed |
| US-8470816-B2 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-06-25 | — | — | US | disclosed |
| US-20120277238-A1 | PHARMACEUTICAL COMPOSITION CONTAINING FUSED HETERO-RING DERIVATIVE | SHIONOGI & CO., LTD (JP) | 2012-11-01 | — | — | US | disclosed |
| US-20120277238-A1 | PHARMACEUTICAL COMPOSITION CONTAINING FUSED HETERO-RING DERIVATIVE | SHIONOGI & CO., LTD (JP) | 2012-11-01 | — | — | US | disclosed |
| EP-2460794-A1 | PHARMACEUTICAL COMPOSITION CONTAINING FUSED HETERO-RING DERIVATIVE | Shionogi & Co., Ltd. (JP) | 2012-06-06 | — | — | EP | disclosed |
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-06-18 | — | — | US | disclosed |
| WO-2009072643-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250313548-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS KCNT1 INHIBITORS | KCNT1, KCNT2, KCNN3 | ALOX15 3201/4885NFKB1 3463/4885BLM 1974/4885 |
| US-20120277238-A1 | PHARMACEUTICAL COMPOSITION CONTAINING FUSED HETERO-RING DERIVATIVE | HRH4, HRH3, HRH2 | ALOX15 2446/4885NFKB1 1938/4885BLM 3557/4885 |
| US-12630533-B2 | Heterocyclic compounds useful as KCNT1 inhibitors | KCNT1, KCNT2, KCNJ2 | ALOX15 2936/4885NFKB1 3765/4885BLM 3621/4885 |
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | NTSR2, NTSR1, HNMT | ALOX15 1041/4885NFKB1 1724/4885BLM 3989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.